Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

NCT02373072 ·Status: COMPLETED ·Phase: PHASE1

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866 ·Status: COMPLETED ·Phase: PHASE4

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

NCT00321854 ·Status: COMPLETED ·Phase: PHASE4

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

NCT00297778 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate in Patients With Parkinsonian Type Disorders

NCT03683225 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

NCT00479401 ·Status: COMPLETED ·Phase: PHASE3

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300 ·Status: COMPLETED ·Phase: PHASE4

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

NCT02233023 ·Status: COMPLETED ·Phase: PHASE4

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

NCT02236728 ·Status: COMPLETED

Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease

NCT01097421 ·Status: COMPLETED

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

NCT01361009 ·Status: COMPLETED

Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations

NCT06614153 ·Status: COMPLETED ·Phase: PHASE2

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

NCT01673724 ·Status: COMPLETED ·Phase: PHASE4

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

NCT01634360 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

NCT01525641 ·Status: COMPLETED

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

NCT01096186 ·Status: COMPLETED ·Phase: PHASE3

Pivotal Study in Advanced Parkinsons Disease Patients

NCT00466167 ·Status: COMPLETED ·Phase: PHASE3

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

NCT00163085 ·Status: COMPLETED ·Phase: PHASE2

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

NCT00651183 ·Status: COMPLETED

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

NCT02248168 ·Status: COMPLETED

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

NCT00560508 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233 ·Status: COMPLETED ·Phase: PHASE4

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

NCT02565628 ·Status: COMPLETED ·Phase: PHASE1

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

NCT01470859 ·Status: COMPLETED ·Phase: NA

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508 ·Status: COMPLETED ·Phase: PHASE3